AIDEVI Science & Wellness Guide
What Is nmnH? Reduced NMN, Research, and Safety
NMNH, or dihydronicotinamide mononucleotide, is the reduced form of NMN. Laboratory and animal studies have found effects on NAD-related metabolism, and a 2026 preprint reports an early 90-day human study of NMNH calcium salt. That report has not been peer reviewed. The evidence is not yet enough to establish a standard dose, long-term safety, or a proven health benefit for consumers.
- NMNH is a distinct reduced form of NMN. It is not another name for NMN, NR, or NRH.
- Cell and mouse studies report changes in NAD+ and NADH metabolism; those results are preclinical.
- One 2026 preprint reports a 90-day randomized study of NMNH-Ca in 80 adults, but the findings have not been peer reviewed or independently replicated.
- A blood NAD+ change does not, on its own, demonstrate more energy, slower aging, or a clinical benefit.
What does NMNH mean?
NMNH stands for dihydronicotinamide mononucleotide. It is commonly described as reduced NMN because the two molecules are closely related, while NMNH is in a reduced redox state. “Reduced” is a chemistry term for a difference in electron and hydrogen status. It does not mean that NMNH is automatically absorbed better, works faster, or is more effective in people.[1][2]
A few related names are easy to mix up. NMN is nicotinamide mononucleotide. NMNH is its reduced form. NR is nicotinamide riboside, while NRH is reduced nicotinamide riboside. The shared letters reflect related chemistry, not identical ingredients or interchangeable study results.
NAD+ and NADH are coenzymes involved in cellular reactions; NMN and NMNH are precursor molecules studied in relation to NAD metabolism. These terms describe different roles. If your main question is whether NMNH or NMN is the better supplement choice, use AIDEVI’s separate NMNH vs. NMN comparison. This page focuses on what NMNH is and what the research can currently tell us.
How does NMNH relate to NAD+ metabolism?
NAD+ is used in many cellular reactions, including those involved in energy metabolism and signaling. Cells also use NADH, its reduced counterpart, and regulate the balance between NAD+ and NADH according to the needs of different pathways and cellular compartments. This network is more complicated than a simple promise that “more NAD+ means more energy.”
In laboratory research, NMNH has been studied as a reduced NAD+ precursor. One study reported that it could increase NAD+ and NADH through a pathway involving NMN adenylyltransferase (NMNAT), with results differing from those observed for NMN in the tested cells and mice.[1][2] These observations help researchers form hypotheses about NMNH metabolism. They do not establish how a particular oral product is absorbed or used in every person.
| Term | What it describes | What not to assume |
|---|---|---|
| NAD+ | An oxidized coenzyme used in cellular reactions. | A higher blood measurement alone proves better health or energy. |
| NADH | The reduced counterpart of NAD+. | More NADH automatically improves energy production. |
| NMN | A molecule involved in NAD+ biosynthesis. | Every NMN product or study has the same formulation or outcome. |
| NMNH | The reduced form of NMN, studied as a distinct NAD+ precursor. | Cell or mouse findings guarantee a human effect or define a consumer dose. |
| NRH | The reduced form of nicotinamide riboside. | NRH and NMNH are the same compound. |
For foundational NAD+ and NMN terminology, see AIDEVI’s guide to NAD+ versus NMN.
What have cell and animal studies found?
A 2021 study in cultured cells and mice reported that NMNH increased NAD+ more than NMN under the experimental conditions. The researchers also observed higher NADH and changes in energy-related pathways, including suppression of glycolysis and the tricarboxylic acid (TCA) cycle in the models studied. In cell experiments, they reported reduced cell growth.[1]
A separate 2021 study examined NMNH in mammalian cells and mice. It described increased NAD+ in several tissues after administration in mice and explored a metabolic route distinct from some better-known NAD+ precursor pathways.[2] Together, these papers make NMNH a legitimate subject for further study, but they remain preclinical evidence.
The cell-growth and metabolic findings should be read in context. They do not show that taking NMNH causes the same changes in a human body, and they do not establish harm from a supplement. They do show why a large NAD+ measurement should not automatically be marketed as “stronger energy,” “faster recovery,” or “better aging.” A pathway change may be useful, neutral, or undesirable depending on the tissue, context, and outcome.
Cell and animal studies are valuable for asking how a molecule may work and what deserves closer safety monitoring. They cannot establish whether an oral supplement improves quality of life, physical function, metabolic health, or lifespan in people.
What does the early human research show?
A 2026 report adds an initial human data point. The randomized, double-blind, placebo-controlled phase I study described 80 adults aged 40 to 65 who received placebo or NMNH calcium salt (NMNH-Ca) at 125, 250, or 500 mg daily for 90 days. The authors reported dose-related increases in whole-blood NAD+ and no serious or treatment-related adverse events during the study period.[3]
This report is a preprint and has not been peer reviewed. The study was small, short, and tested one specific calcium-salt formulation. Most participants were men, all participants were Asian, and several outcomes—such as walking distance, quality-of-life scores, and a biomarker-derived “phenotypic age”—were exploratory. The reported results need formal peer review, independent replication, and longer follow-up before they can support broad claims about NMNH supplements.
The distinction between a study and a product claim matters. The study can inform questions about the tested NMNH-Ca formulation, dose schedule, participants, and measured endpoints. It cannot tell consumers that every NMNH product has the same salt form, amount, stability, manufacturing quality, or effect. It also does not establish a dose recommendation for the public.
For additional context, published NMN research includes small human trials and reviews, but results vary by population, formulation, duration, and outcome. A 2026 meta-analysis found generally favorable short-term tolerability while reporting no clear broad metabolic benefits and calling for larger, longer trials.[4] AIDEVI’s NMN guide to human research and safety covers that evidence in more detail.
What can we conclude about NMNH today?
- Ingredient identity: NMNH is the reduced form of NMN; it is distinct from NMN, NR, and NRH.
- Biology: cell and animal studies suggest NMNH can affect NAD+ and NADH metabolism, but those results do not predict a guaranteed human response.
- Human evidence: a recent preprint reports a small, 90-day NMNH-Ca study. It is preliminary and has not been peer reviewed.
- Open questions: independent replication, longer-term safety, formulation-specific testing, effects in different populations, and meaningful outcomes beyond a blood biomarker.
The fairest description is that NMNH is an emerging NAD+ precursor with promising early research and substantial unanswered questions. Calling it a proven anti-aging supplement or a clinically superior NAD+ booster goes beyond the evidence described here.
How should you review an NMNH product claim?
Start with the exact ingredient name and supporting information, not with a “next-generation” or “stronger NAD+” headline. A careful product review separates identity, quality, and effectiveness. Evidence that supports one of those questions does not automatically answer the others.
- Confirm the form. Look for NMNH or the full chemical name, and note whether the material is identified as a calcium salt. Do not assume an NMN study applies to NMNH-Ca.
- Read the serving information. Check the amount, number of capsules, additional ingredients, storage instructions, and warnings. Study doses are not personal instructions.
- Check the document trail. If a certificate of analysis is available, see whether it connects to the product lot and says what sample was tested, which method was used, and what result was measured. For a reduced ingredient, ask whether the method distinguishes NMNH from NMN.
- Keep quality separate from benefit. A laboratory report can support selected identity or purity conclusions. It cannot prove that NMNH will improve energy, reverse aging, or prevent disease. See AIDEVI’s guide to reading a certificate of analysis for a checklist of what a report can and cannot show.
If a claim relies on a cell study, ask what was tested and what the model can tell us. If it relies on the 2026 NMNH-Ca preprint, ask whether the product matches the tested form and remember the report has not yet passed peer review. Do not interpret a missing public document as proof of a problem; ask the company what evidence is available for the exact batch.
Safety, dose, and combining NMNH with other precursors
There is not enough evidence to set a general NMNH dose for consumers. The 125, 250, and 500 mg amounts in the preprint apply to the study’s NMNH-Ca material and protocol; they are not a dosage recommendation and should not be transferred to another formulation.[3]
A 90-day study in a selected group cannot establish long-term safety for every adult. People may differ in health status, medication use, diet, and other supplements. The early findings should not be used to dismiss possible risks or interactions that were not measured in a small trial.
The studies reviewed here also do not establish that taking NMNH together with NMN or NR improves outcomes. Combining several precursors may add cost and make it harder to identify which product caused a benefit or an unwanted effect. Anyone who is pregnant or nursing, takes medication, manages a health condition, is preparing for surgery, or has persistent unexplained symptoms should consult a qualified healthcare professional before starting a new supplement.
If a product causes a concerning or persistent reaction, stop using it and seek appropriate medical advice. A general article cannot assess an individual’s medication list or health risks.
Frequently asked questions
Is NMNH the same as NMN?
No. NMNH is the reduced form of NMN. They are related but distinct chemical forms, and their research findings should not be treated as interchangeable.
Is NMNH the same as NRH?
No. NRH is reduced nicotinamide riboside. NMNH is reduced nicotinamide mononucleotide. The abbreviations are similar, but the compounds differ.
Has NMNH been tested in people?
A 2026 preprint reports a 90-day randomized study of NMNH calcium salt in 80 adults. The findings are preliminary and not peer reviewed. The study does not establish long-term safety or prove the results apply to every NMNH product.[3]
Does NMNH increase NAD+?
Cell and animal studies report increases in NAD-related measurements, and the NMNH-Ca preprint reports increased whole-blood NAD+ in its study groups. These findings do not by themselves prove a health benefit or a noticeable change for an individual.
Is NMNH better than NMN?
No direct human study discussed here establishes that NMNH is better. NMNH has emerging research; NMN has more published human supplementation data. For a focused comparison of evidence and decision factors, see the NMNH vs. NMN guide.
Is there a standard NMNH dose?
A general dose has not been established by the evidence reviewed here. The doses used in one research protocol should not be treated as a recommendation for a different NMNH form or for an individual consumer.
References
- Liu Y, et al. “Reduced Nicotinamide Mononucleotide (NMNH) Potently Enhances NAD+ and Suppresses Glycolysis, the TCA Cycle, and Cell Growth.” Journal of Proteome Research. 2021;20(5):2596–2606. PubMed.
- Zapata-Pérez R, et al. “Reduced nicotinamide mononucleotide is a new and potent NAD+ precursor in mammalian cells and mice.” The FASEB Journal. 2021;35(4):e21456. doi:10.1096/fj.202001826R.
- Li J, et al. “Safety and Exploratory Efficacy of Reduced β-Nicotinamide Mononucleotide Calcium Salt (NMNH-Ca) in Healthy Middle-Aged and Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial.” medRxiv. Posted August 12, 2026. Preprint; not peer reviewed. doi:10.64898/2026.08.11.26360226.
- Yang W, et al. “Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.” Nutrients. 2026;18(14):2251. PubMed.
Individual results may vary. Consult a healthcare professional before starting any new supplement, especially if pregnant, nursing, taking medication, or managing a medical condition. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
